BCL2 and myelodysplastic syndrome: As an emerging treatment method, the combination of a BCL-2 inhibitor and an immune checkpoint inhibitor may be a new potential therapy for HR-MDS/AML patients, and corresponding clinical research is currently underway (NCT03390296) [42, 43].